

This material is an English translation of the press release announced on Jan. 14, 2022 in Japanese, and the Japanese release is given priority about the content and the interpretation.

Jan. 14, 2022

**Notice regarding Results and Completion of Acquisition of Treasury Shares**

(Acquisition of treasury shares in accordance with the provisions of the Articles of Incorporation pursuant to Article 165, Paragraph 2 of the Companies Act)

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu, Saga; President and CEO: NAKATOMI Kazuhide;) announces that we have acquired treasury shares as follows, in accordance with the provisions of Article 156 of the Companies Act, which is applied by replacing the terms pursuant to the provisions of Article 165, Paragraph 3 of the said Act.

We are also pleased to announce that the acquisition of treasury shares based on the resolution of the board of directors held on October 14, 2021 has been completed with the following acquisition.

1. Type of shares acquired: Common share of the Company
2. Total number of shares acquired: 2 million shares
3. Total amount of value of shares acquired: 8,041,487,000 yen
4. Acquisition period: November 11, 2021 to January 13, 2022
5. Method of acquisition: Market purchase on the Tokyo Stock Exchange

(Reference information)

Resolutions at the board of directors held on October 14, 2021

1. Type of shares to be acquired: Common share of the Company
2. Total number of shares that can be acquired: 2 million shares (upper limit)  
(2.45% of total number of shares issued (excluding treasury shares))
3. Total amount of value of shares acquired: 12 billion yen (upper limit)
4. Acquisition period: October 15, 2021 to February 28, 2022